Abstract:Clinically, high density lipoprotein (HDL) is known to be a potent negative risk factor of cardiovascular disease due to its ability to stimulate anti‐atherosclerotic, anti‐inflammation and antioxidant pathways. It has been established that HDL has a role in the innate immune system through its ability to sequester lipopolysaccharide (LPS) or lipoteichoic acid (LTA) in the blood. This sequestering prevents the endotoxins from binding to their respective toll‐like receptors and subsequently stimulating the transcription of pro‐inflammatory cytokines. Elevated HDL levels are seen to attenuate sepsis by rapidly removing LPS molecules from the blood. LPS molecules appear to bind to the apoproteins contained on the periphery of the HDL particles. The binding of LPS to apoproteins, specifically ApoA1, causes a conformational change to the apoproteins. These conformational changes may inhibit the apoprotein's abilities to interact with cell surface receptors. It is not known how the binding of LPS affects HDL's other beneficial roles. Along with its anti‐inflammatory role, HDL's ability to prevent the oxidation of LDL particles is seen as one of the major mechanisms in preventing atherosclerosis. ApoA1 is necessary for reverse cholesterol transport through interaction with the cell membrane transporter ABCA1 and is needed for HDL's inhibition of NADPH oxidase. ApoA1 and/or the other apoproteins contained on the surface of the HDL molecule may be mechanistically involved in HDL's anti‐oxidative effects, effects which may be inhibited by the presence of LPS. It is not yet known how LPS from chronic inflammation or metabolic endotoxemia will affect HDL function. The ability of LPS to inhibit HDLs interactions with human skeletal muscle cells and prevent reactive oxygen species (ROS) production was assessed. Skeletal muscle myoblasts were isolated from the vastus lateralis of human skeletal muscle tissue collected from young (22.9 years +/− 0.9) lean (Mean BMI 23.2+/− 0.6) donors. Cells were grown to ~ 80% confluence and differentiated for seven days. For 24 hours, differentiated muscle cells were incubated in a starvation media (serum free, low glucose DMEM (5.5mM) or a high glucose DMEM (25 mM) plus LPS (20 EU/ml)(from E. coli). Each of these conditions were tested with and without the presence of human derived HDL (50ug/ml). The rate of ROS production was measured using CM‐H2DCFDA (general oxidative stress indicator) kit. Oxidative markers, including 4‐hydroxynonenal (4‐HNE), were measured through immunocytochemistry florescence. HDL treatment, under starvation conditions in the absence of LPS, was effective at reducing both ROS production (−14.5%) and oxidative stress (4‐HNE, −12.6%). HDL, when added to the high glucose plus LPS condition, had no effect on ROS production when compared to the high glucose plus LPS condition without HDL. The addition HDL to the high glucose plus LPS treatment increased 4‐HNE content by 13.0% compared to treatment of high glucose and LPS without HDL. The anti‐oxidative capacity of HDL was not observed in the presence of LPS and elicited greater oxidative stress, possibly due to increased LPS‐HDL binding. This data suggest that the anti‐inflammatory effect of HDL may come at the cost of its other biological functions. It also suggests that chronic low‐grade endotoxemia may counter the clinical significance of HDL as a negative risk factor for cardiovascular and metabolic disease disease. Support or Funding Information American Diabetes Association (ADA‐07–12) and National Institutes of Health (1RO1DK078765)

Effect of high-density lipoprotein on adipocytes stimulated by lipopolysaccharide

Effect of high-density lipoprotein on interleukin-8 secretion in 3T3-L1 adipocytes

High-density Lipoprotein Increases the Uptake of Oxidized Low Density Lipoprotein Via PPARγ/CD36 Pathway in Inflammatory Adipocytes

[Study on the Protective Effect of HDL Subclasses Against Lipopolysaccharide].

The Beneficial Effects Of High-Density Lipoprotein On Adipocytes May Relate To Its Anti-Atherogenic Properties

High-density lipoprotein attenuates lipopolysaccharide-induced acute lung injury in mice]

Effects of High Density Lipoprotein and Apolipoprotein A-I Mimetic Peptide on the Expression of Adiponectin in 3T3-L1 Adipocytes

[Effects of Oxidized Low-Density Lipoprotein on Cholesterol Efflux in 3T3-L1 Cells].

Role of High Density Lipoprotein in Protecting Against Endotoxin Toxicity

High Density Lipoprotein‐Lipopolysaccharide Binding Lowers HDL's Basal Antioxidant Capacity

Influences of high density lipoprotein and atorvastatin on inflammatory reaction in 3T3-L1 adipocytes stimulated by oxLDL

Dual Effects of Oxidized Low-Density Lipoprotein on LXR-ABCA1-apoA-I Pathway in 3T3-L1 Cells.

Effect of Lipid-Bound Apoa-I Cysteine Mutants on Lipopolysaccharide-Induced Endotoxemia in Mice.

High Density Lipoprotein 3 Inhibits Oxidized Low Density Lipoprotein-Induced Apoptosis Via Promoting Cholesterol Efflux in RAW264.7 Cells

L-4f Inhibits Oxidized Low-Density Lipoprotein-Induced Inflammatory Adipokine Secretion Via Cyclic Amp/Protein Kinase A-Ccaat/Enhancer Binding Protein Beta Signaling Pathway In 3t3-L1 Adipocytes

High Density Lipoprotein Suppresses Lipoprotein Associated Phospholipase A2 in Human Monocytes-Derived Macrophages Through Peroxisome Proliferator-Activated Receptor-Γ Pathway.

High Density Lipoprotein Can Defense Mouse Damage Induced by Endotoxin

Lipopolysaccharides Reduce Adipogenesis in 3T3-L1 Adipocytes Through Activation of NF-κB Pathway and Downregulation of AMPK Expression

Enzyme-digested Colla Corii Asini (E'jiao) suppresses lipopolysaccharide-induced inflammatory changes in THP-1 macrophages and OP9 adipocytes

The Effects of Low Density Lipoprotein on the Adhesion Force of Endothelial Cells and Extracelluar Matrix

[Combined Effect of High Mobile Group Box-1 Protein and Lipopolysaccharide on Release of Cytokines from Human HepG2 Cells].